Ikonisys Announces the Successful Deployment of the Commercial Strategy With the Second Sale of the Ikoniscope20max Solution
28 7월 2023 - 2:30PM
Business Wire
Regulatory News:
Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic: ALIKO),
a company specializing in the early and accurate detection of
cancer with a unique fully-automated solution for medical
diagnostic labs, announces the second successful sale and
installation of the Ikoniscope20max, the new configuration of the
Ikoniscope20 with a high-volume slide loader. The second client is
a specialized urology laboratory in the Midwest USA, that required
the fully automated slide loader system to simplify its
high-throughput workflow.
This sale follows the one previously announced on June 21, 2023
at another important site where the instrument has been internally
tested and fully validated, resulting in its daily utilization for
routine clinical testing. These successes highlight the value
proposition of the Ikoniscope20max for laboratories, its
operational efficiency and the effective deployment of the
commercial strategy.
Jurgen Schipper, CCO of Ikonisys, stated: “I am
very happy to announce that our roll-out plan for the
Ikoniscope20max is going as planned because the system is very
important for medium/large laboratories, that constitute a valuable
customer base for us. At the same time, we are delighted by the
very positive feedback we received from the first customer of the
new high-volume instrument. The successful internal validation
process obviously proved the validity of the Ikoniscope20max
system, but, more importantly to us, it showed the ease of
operation of our instrument, designed to simplify the life of
technicians and physicians.”
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230727940540/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Aurélie Manavarere/Louis-Victor Delouvrier
Investor Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Ikonisys (EU:ALIKO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
